Trial Profile
Immunogenicity of Human papillomavirus vaccine in immunosuppressed children
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 25 Nov 2019
Price :
$35
*
At a glance
- Drugs Human papillomavirus vaccine recombinant quadrivalent Merck (Primary)
- Indications Cervical cancer; Human papillomavirus infections
- Focus Adverse reactions; Pharmacodynamics
- 22 Nov 2019 Status changed from active, no longer recruiting to completed.
- 21 Nov 2013 Status changed from recruiting to active, no longer recruiting as reported by Australian New Zealand Clinical Trials Registry.
- 13 May 2009 New trial record